CY1693A - Use of ketone derivatives in the treatment of depression - Google Patents

Use of ketone derivatives in the treatment of depression

Info

Publication number
CY1693A
CY1693A CY169394A CY169394A CY1693A CY 1693 A CY1693 A CY 1693A CY 169394 A CY169394 A CY 169394A CY 169394 A CY169394 A CY 169394A CY 1693 A CY1693 A CY 1693A
Authority
CY
Cyprus
Prior art keywords
depression
treatment
ketone derivatives
methyl
ketone
Prior art date
Application number
CY169394A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CY1693A publication Critical patent/CY1693A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Emergency Protection Circuit Devices (AREA)
  • Connection Of Batteries Or Terminals (AREA)
  • Saccharide Compounds (AREA)
  • Electrotherapy Devices (AREA)
CY169394A 1986-12-17 1994-01-14 Use of ketone derivatives in the treatment of depression CY1693A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868630071A GB8630071D0 (en) 1986-12-17 1986-12-17 Medicaments

Publications (1)

Publication Number Publication Date
CY1693A true CY1693A (en) 1994-01-14

Family

ID=10609112

Family Applications (1)

Application Number Title Priority Date Filing Date
CY169394A CY1693A (en) 1986-12-17 1994-01-14 Use of ketone derivatives in the treatment of depression

Country Status (18)

Country Link
US (1) US4835173A (enExample)
EP (1) EP0276559B1 (enExample)
JP (1) JP2732844B2 (enExample)
KR (1) KR880007073A (enExample)
AT (1) ATE79031T1 (enExample)
AU (1) AU608794B2 (enExample)
CY (1) CY1693A (enExample)
DE (1) DE3780940T2 (enExample)
DK (1) DK662787A (enExample)
ES (1) ES2051754T3 (enExample)
GB (1) GB8630071D0 (enExample)
GR (1) GR3005682T3 (enExample)
HK (1) HK36593A (enExample)
IE (1) IE60135B1 (enExample)
IL (1) IL84844A0 (enExample)
NZ (1) NZ222949A (enExample)
PH (1) PH25503A (enExample)
ZA (1) ZA879458B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63277622A (ja) * 1986-12-17 1988-11-15 グラクソ、グループ、リミテッド 医薬
US5246941A (en) * 1986-12-17 1993-09-21 Glaxo Group Limited Method for the treatment of depression
US5221687A (en) * 1988-09-01 1993-06-22 Glaxo Group Limited Medicaments
GB8820653D0 (en) * 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
US5180728A (en) * 1989-09-25 1993-01-19 Fujisawa Pharmaceutical Company, Ltd. Pyrimidoindole derivatives and processes for preparation thereof
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
JPH06508836A (ja) * 1991-06-26 1994-10-06 セプラコア,インコーポレーテッド 光学的に純粋なr(+)オンダンセトロンを使用する嘔吐、吐き気および他の障害の治療のための方法および組成物
US6548082B1 (en) 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
AU2002230935A1 (en) * 2000-10-30 2002-05-15 Teva Pharmaceutical Industries Ltd. Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
EP1207160A1 (en) * 2000-11-20 2002-05-22 Hanmi Pharm. Co., Ltd. Process for the preparation of 1,2,3,9-tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)-methyl)-4H-carbazol-4-one
SK9892003A3 (en) * 2001-01-11 2004-05-04 Teva Pharma An improved process for preparing pure ondansetron hydrochloride dihydrate
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
DK1499623T3 (da) * 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
KR20040104677A (ko) * 2002-04-30 2004-12-10 비오갈 기오기스제르갸르 알티. 신규의 온단세트론 결정 형태, 그 제조 방법, 그 신규의결정 형태를 함유하는 약학 조성물 및 이들을 이용한구역질 치료 방법
HU225885B1 (en) * 2002-10-17 2007-11-28 Richter Gedeon Nyrt Process for producing ondansetron hydrochlorid dihydrate of high purity
US20110034442A1 (en) * 2007-08-08 2011-02-10 Jaun Jose Legarda Ibanez Use and Methods of Use for an Antagonist of the Serotin3 Receptor (5-HT3) and a Selective Modulator of Chloride Channels for the Treatment of Addiction to or Dependence on Medicines/Drugs or Nervous System Disorders
BR112020023132A2 (pt) 2018-06-21 2021-02-09 Société des Produits Nestlé S.A. composições e métodos que usam um precursor de nicotinamida adenina dinucleotídeo (nad+) e pelo menos uma cetona ou um precursor de cetona

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN158970B (enExample) * 1981-06-09 1987-02-28 Ici Plc
GB8401888D0 (en) * 1984-01-25 1984-02-29 Glaxo Group Ltd Heterocyclic compounds
SE460359B (sv) * 1984-01-25 1989-10-02 Glaxo Group Ltd 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
EP0201165B1 (en) * 1985-03-14 1994-07-20 Beecham Group Plc Medicaments for the treatment of emesis
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8518743D0 (en) * 1985-07-24 1985-08-29 Glaxo Group Ltd Heterocyclic compounds
HU895334D0 (en) * 1986-07-30 1990-01-28 Sandoz Ag Process for the preparation of nasal pharmaceutical compositions

Also Published As

Publication number Publication date
KR880007073A (ko) 1988-08-26
IE60135B1 (en) 1994-06-01
PH25503A (en) 1991-07-24
US4835173A (en) 1989-05-30
ES2051754T3 (es) 1994-07-01
EP0276559A3 (en) 1989-10-18
JPS63165314A (ja) 1988-07-08
DE3780940T2 (de) 1992-12-24
IL84844A0 (en) 1988-06-30
NZ222949A (en) 1997-06-24
GB8630071D0 (en) 1987-01-28
EP0276559A2 (en) 1988-08-03
DK662787A (da) 1988-06-18
AU608794B2 (en) 1991-04-18
JP2732844B2 (ja) 1998-03-30
ZA879458B (en) 1988-11-30
GR3005682T3 (enExample) 1993-06-07
IE873415L (en) 1988-06-17
ATE79031T1 (de) 1992-08-15
AU8261787A (en) 1988-06-23
HK36593A (en) 1993-04-23
DK662787D0 (da) 1987-12-16
EP0276559B1 (en) 1992-08-05
DE3780940D1 (de) 1992-09-10

Similar Documents

Publication Publication Date Title
EP0276559A3 (en) Use of ketone derivatives in the treatment of depression
SE8503680D0 (sv) Indolderivat
NO873695D0 (no) Dentalt implantat av skruetypen og fremgangsmaate for bruk av samme.
AU1808488A (en) Compounds for the treatment of alzheimer's disease
EP0276536A3 (en) Use of buspirone for the improvement of short term memory
NO911432D0 (no) Fremgangsmaate for fremstilling av 3,5-disubstituerte 2-isoksazoliner og isoksazoler.
GR3004252T3 (enExample)
IE873414L (en) Medicament for dementia
NO893826L (no) Fremgangsmaate for fremstilling av 2'-halomethyliden, 2'-ethenyliden og 2'-ethenyladenosinderivater.
GR3003327T3 (en) Substituted 1,8-naphthyridine derivatives and fungicides containing them
DE3567211D1 (en) (pyrrol-1-yl)-phenyl-dihydropyridazinones, their preparation and use
FR2630907B1 (fr) Cotyle visse, notamment pour prothese du type " de hanche "
NO921086D0 (no) Fremgangsmaate for fremstilling og anvendelse av substituerte 2',3'-didesoksy-5-trifluormetyluridiner
IE873231L (en) Medicaments
GR74782B (enExample)
ZA874878B (en) Pyran derivatives
NZ223203A (en) Herbicidal compositions containing tetrahydrophthalimides and 1,3,5-triazin-2-yl-urea derivatives
李虎容 et al. OCCLUSAL CONSIDERATION FOR IMPLANTS
CS310487A1 (en) Connection for amplifier's output stage's transistor operating point adjustment
FI882378A7 (fi) Tandlaekarens patientstol.
MY102564A (en) An indole derivative
IT1217080B (it) Acetabolo perfezionato per protesi d'anca.
IT8722869V0 (it) Dispositivo perfezionato per l'abbronzatura artificiale integrale o parziale.
IL85508A0 (en) Benzylaminoaryl-dihydropyridinelactones,their preparation and their use in medicaments